Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) and Mustang Bio (NASDAQ:MBIO – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation and dividends.
Insider and Institutional Ownership
10.0% of Mustang Bio shares are held by institutional investors. 4.3% of Agios Pharmaceuticals shares are held by company insiders. Comparatively, 4.0% of Mustang Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Analyst Recommendations
This is a summary of recent ratings and price targets for Agios Pharmaceuticals and Mustang Bio, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Agios Pharmaceuticals | 1 | 4 | 6 | 1 | 2.58 |
| Mustang Bio | 1 | 0 | 0 | 0 | 1.00 |
Valuation & Earnings
This table compares Agios Pharmaceuticals and Mustang Bio”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Agios Pharmaceuticals | $44.79 million | 35.36 | $673.72 million | ($7.00) | -3.88 |
| Mustang Bio | N/A | N/A | -$15.75 million | ($0.31) | -3.10 |
Agios Pharmaceuticals has higher revenue and earnings than Mustang Bio. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than Mustang Bio, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Agios Pharmaceuticals and Mustang Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Agios Pharmaceuticals | -895.86% | -28.35% | -26.42% |
| Mustang Bio | N/A | -75.33% | -16.50% |
Volatility and Risk
Agios Pharmaceuticals has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500. Comparatively, Mustang Bio has a beta of 2.08, indicating that its stock price is 108% more volatile than the S&P 500.
Summary
Agios Pharmaceuticals beats Mustang Bio on 8 of the 14 factors compared between the two stocks.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
About Mustang Bio
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
